Trial
NCT04118036
Abemaciclib + Pembrolizumab In Glioblastoma
Phase IIWITHDRAWNSAFETYConfidence: MEDIUM
Sponsor
Dana-Farber Cancer Institute
Collaborators
—
Condition
Glioblastoma
Intervention
Pembrolizumab
Why stopped
safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-11